Comparative Pharmacology
Head-to-head clinical analysis: PIMECROLIMUS versus SANDIMMUNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMECROLIMUS versus SANDIMMUNE.
PIMECROLIMUS vs SANDIMMUNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.
None Documented
None Documented
Clinical Note
moderatePimecrolimus + Gatifloxacin
"Pimecrolimus may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePimecrolimus + Rosoxacin
"Pimecrolimus may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePimecrolimus + Levofloxacin
"Pimecrolimus may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePimecrolimus + Trovafloxacin
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Terminal elimination half-life is approximately 8.4 hours (range 6–24 hours) in adults; prolonged in patients with hepatic impairment.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Primarily biliary/fecal (94% of metabolites); renal elimination is minimal (<6% as unchanged drug and metabolites).
Category A/B
Category C
Calcineurin Inhibitor
Calcineurin Inhibitor
"Pimecrolimus may increase the neuroexcitatory activities of Trovafloxacin."